14-day Premium Trial Subscription Sign Up For FreeGet Free

Arbutus Biopharma Corporation Stock Forecast NASDAQ:ABUS

$2.68 (-4.63%)

Volume: 5M

Closed: Jan 21, 2022

Hollow Logo Score: -4.781

Arbutus Biopharma Corporation Stock Forecast

$2.68 (-4.63%)

Volume: 5M

Closed: Jan 21, 2022

Score Hollow Logo -4.781

Arbutus Biopharma Corporation Stock News NASDAQ:ABUS

Arbutus Biopharma Corporation (NASDAQ:ABUS) with the stream of 0.00% also noticed, India Banco Santander, S.A. (NYSE:SAN) encountered a rapid change of 2.84% in the last hour of Thursdays trading session. The post Stock is blowing up: Arbutus Biopharma Corporation (NASDAQ:ABUS), Banco Santander, S.A. (NYSE:SAN) appeared first on Stocks Equity . Read more

Arbutus Biopharma (NASDAQ:ABUS) Shares Down 2.9%

05:38pm, Thursday, 23'rd Dec 2021 Transcript Daily
Arbutus Biopharma Co. (NASDAQ:ABUS) traded down 2.9% during trading on Thursday . The company traded as low as $4.00 and last traded at $4.04. 60,266 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 25,955,150 shares. The stock had previously closed at $4.16. A number of equities research [] Read more
The "RNAi for Therapeutic" Market report offers qualitative and quantitative insights and a detailed analysis of market size & growth rate for all possible segments in the market. The Global RNAi for Therapeutic Industry presents a market overview, product details, Read more
Equities research analysts expect Arbutus Biopharma Co. (NASDAQ:ABUS) to report sales of $3.39 million for the current quarter, Zacks reports. Two analysts have issued estimates for Arbutus Biopharmas earnings, with the highest sales estimate coming in at $3.47 million and the lowest estimate coming in at $3.30 million. Arbutus Biopharma posted sales of $2.39 million [] Read more
Equities analysts expect Arbutus Biopharma Co. (NASDAQ:ABUS) to announce earnings of ($0.18) per share for the current quarter, Zacks reports. Two analysts have made estimates for Arbutus Biopharmas earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.19). Arbutus Biopharma reported earnings per share of ($0.23) in [] Read more
MENDHAM, N.J. and WARMINSTER, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection. A single cohort in the ongoing Antios Phase 2a SAVE-1 (Sustained Anti-Viral Efficacy) clinical trial will evaluate a triple combination of Antios’ proprietary active site polymerase inhibitor nucleotide (ASPIN), ATI-2173, Arbutus’ proprietary GalNAc delivered RNAi therapeutic, AB-729, and tenofovir disoproxil fumarate (TDF), a nucleotide reverse transcriptase inhibitor. Read more
Brokerages expect Arbutus Biopharma Co. (NASDAQ:ABUS) to post $3.39 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Arbutus Biopharma’s earnings. The highest sales estimate is $3.47 million and the lowest is $3.30 million. Arbutus Biopharma reported sales of $2.39 million in the same quarter last year, […] Read more

Arbutus Biopharma Corporation (NASDAQ: ABUS): Would You Buy Today?

03:30pm, Monday, 13'th Dec 2021 Marketing Sentinel
In the last trading session, 7.06 million shares of the Arbutus Biopharma Corporation (NASDAQ:ABUS) were traded, and its beta was 2.60. Most recently the company’s share price was $4.14, and it changed around -$0.17 or -3.94% from the last close, which brings the market valuation of the company to $581.59M. ABUS currently trades at a … Arbutus Biopharma Corporation (NASDAQ: ABUS): Would You Buy Today? Read More » Read more
(RTTNews) - Arbutus Biopharma Corp. (ABUS) and Qilu Pharmaceutical announced an exclusive licensing agreement and strategic partnership to develop and commercialize AB-729 for the treatment or prevention of hepatitis B in mainland China, Hong Kong, Macau and Taiwan. As per the agreement, Arbutus would receive a $40 million upfront payment and Read more
NEW YORK , Dec. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LCID, ET, ARDX, IINN, and ABUS. Full story available on Benzinga.com Read more
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Eye-popping stocks: Arbutus Biopharma Corporation (NASDAQ:ABUS 4.11%), CVS Health Corporation (NYSE:CVS 4.52%) appeared first on Stocks Equity . Read more

Arbutus Biopharma (NASDAQ:ABUS) Trading Up 4.6%

04:44pm, Thursday, 09'th Dec 2021 Transcript Daily
Arbutus Biopharma Co. (NASDAQ:ABUS) shares were up 4.6% during mid-day trading on Thursday . The stock traded as high as $4.42 and last traded at $4.33. Approximately 48,112 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 3,942,938 shares. The stock had previously closed at $4.14. A number [] Read more
Brokerages predict that Arbutus Biopharma Co. (NASDAQ:ABUS) will post earnings of ($0.18) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Arbutus Biopharmas earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.19). Arbutus Biopharma posted earnings per share [] Read more
Arbutus Biopharma Corporation (NASDAQ: ABUS ) has identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease (Mpro), a validated target for treating COVID-19 and potential future coronavirus outbreaks. In April 2021, Arbutus, X-Chem Inc , and Proteros biostructures GmbH entered a discovery Full story available on Benzinga.com Read more
Screening identifies several unique compound series that inhibit the SARS-CoV-2 nsp5 main protease, a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks Read more

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE